Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR.

Nature. 2019 Oct 30. doi: 10.1038/s41586-019-1694-1. [Epub ahead of print]

PMID:
31666701
2.

Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma.

Li R, Shinde A, Fakih M, Sentovich S, Melstrom K, Nelson R, Glaser S, Chen YJ, Goodman K, Amini A.

J Natl Compr Canc Netw. 2019 Oct 1;17(10):1203-1210. doi: 10.6004/jnccn.2019.7309.

PMID:
31590155
3.

Addressing the Overuse of Cultures to Optimize Patient Care.

Vaughn VM, Szymczak JE, Newton DW, Fakih MG.

Ann Intern Med. 2019 Oct 1;171(7_Supplement):S73-S74. doi: 10.7326/M18-3442. No abstract available.

PMID:
31569221
4.

Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.

Gong J, Robertson MD, Kim E, Fakih M, Schrock AB, Tam KW, Burugapalli B, Monjazeb AM, Hendifar AE, Hitchins M, Klempner SJ, Cho M.

Clin Colorectal Cancer. 2019 Sep 4. pii: S1533-0028(19)30282-8. doi: 10.1016/j.clcc.2019.08.001. [Epub ahead of print] No abstract available.

PMID:
31563511
5.

Classification of bloodstream infections in patients recently discharged from acute-care facilities: Hospital acquired or healthcare-associated community onset?

Khatib R, Sharma M, Fakih MG, Riederer KM, Johnson LB.

Infect Control Hosp Epidemiol. 2019 Nov;40(11):1313-1315. doi: 10.1017/ice.2019.245. Epub 2019 Sep 19.

PMID:
31535608
6.

A Survey of Chemoprophylaxis Techniques in Spine Surgery Among American Neurosurgery Training Programs.

Macki M, Haider SA, Anand SK, Fakih M, Elmenini J, Suryadevara R, Chang V.

World Neurosurg. 2019 Sep 13. pii: S1878-8750(19)32463-5. doi: 10.1016/j.wneu.2019.09.033. [Epub ahead of print]

PMID:
31525483
7.

Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.

Fakih M, Ouyang C, Wang C, Tu TY, Gozo MC, Cho M, Sy M, Longmate JA, Lee PP.

J Clin Invest. 2019 Oct 1;129(10):4464-4476. doi: 10.1172/JCI127046.

8.

PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment.

Chen JA, Esteghamat N, Kim EJ, Garcia G, Gong J, Fakih MG, Bold RJ, Cho MT.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1026-1030. doi: 10.6004/jnccn.2019.7328.

PMID:
31487676
9.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.

Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI.

Clin Cancer Res. 2019 Aug 4. doi: 10.1158/1078-0432.CCR-19-1324. [Epub ahead of print]

PMID:
31383735
10.

The case for a population standardized infection ratio (SIR): A metric that marries the device SIR to the standardized utilization ratio (SUR).

Fakih MG, Huang RH, Bufalino A, Erlinger T, Sturm L, Hendrich A, Haydar Z.

Infect Control Hosp Epidemiol. 2019 Sep;40(9):979-982. doi: 10.1017/ice.2019.175. Epub 2019 Jun 24.

PMID:
31232260
11.

Root growth and force chains in a granular soil.

Fakih M, Delenne JY, Radjai F, Fourcaud T.

Phys Rev E. 2019 Apr;99(4-1):042903. doi: 10.1103/PhysRevE.99.042903.

PMID:
31108586
12.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Oct;24(10):1340-1347. doi: 10.1634/theoncologist.2019-0034. Epub 2019 Apr 30.

PMID:
31040255
13.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M.

Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134.

PMID:
31038663
14.

Diagnosis of urinary tract infections: need for a reflective rather than reflexive approach.

Fakih MG, Advani SD, Vaughn VM.

Infect Control Hosp Epidemiol. 2019 Jul;40(7):834-835. doi: 10.1017/ice.2019.98. Epub 2019 Apr 29. No abstract available.

PMID:
31030695
15.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators.

Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

PMID:
31003911
16.

The evolution of catheter-associated urinary tract infection (CAUTI): Is it time for more inclusive metrics?

Advani SD, Fakih MG.

Infect Control Hosp Epidemiol. 2019 Jun;40(6):681-685. doi: 10.1017/ice.2019.43. Epub 2019 Mar 27.

PMID:
30915925
17.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J.

J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.

PMID:
30892987
18.

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J.

Lancet Oncol. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8.

PMID:
30857956
19.

Systemic treatment for metastatic colorectal cancer in the era of precision medicine.

Sandhu J, Lavingia V, Fakih M.

J Surg Oncol. 2019 Apr;119(5):564-582. doi: 10.1002/jso.25421. Epub 2019 Feb 25. Review.

PMID:
30802315
20.
21.

A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction.

Gong J, Cho M, Gupta R, Synold TW, Frankel P, Ruel C, Fakih M, Chung V, Lim D, Chao J.

Oncologist. 2019 Aug;24(8):1137-1145. doi: 10.1634/theoncologist.2018-0336. Epub 2019 Feb 1.

PMID:
30710067
22.

Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme.

Li YJ, Du L, Wang J, Vega R, Lee TD, Miao Y, Aldana-Masangkay G, Samuels ER, Li B, Ouyang SX, Colayco SA, Bobkova EV, Divlianska DB, Sergienko E, Chung TDY, Fakih M, Chen Y.

Cell Chem Biol. 2019 Feb 21;26(2):278-288.e6. doi: 10.1016/j.chembiol.2018.10.026. Epub 2018 Dec 20.

PMID:
30581133
23.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.

Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28.

PMID:
30487236
24.

Clinching the cause: A review of foot drop secondary to lumbar degenerative diseases.

Macki M, Lim S, Elmenini J, Fakih M, Chang V.

J Neurol Sci. 2018 Dec 15;395:126-130. doi: 10.1016/j.jns.2018.09.036. Epub 2018 Oct 1. Review.

PMID:
30316068
25.

Culturing practices and the care of the urinary catheter in reducing NHSN-defined catheter-associated urinary tract infections: The tale of two teaching hospitals.

Bardossy AC, Williams T, Jones K, Szpunar S, Zervos M, Alangaden G, Reyes K, Fakih MG.

Infect Control Hosp Epidemiol. 2018 Dec;39(12):1494-1496. doi: 10.1017/ice.2018.251. Epub 2018 Oct 10.

PMID:
30303048
26.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ.

J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.

27.

The Impact of Different Postgraduate Year Training in Neurosurgery Residency on 30-Day Postoperative Outcomes.

Macki M, Fakih M, Rubinfeld I, Chang V, Walters BC.

Neurosurgery. 2019 Mar 1;84(3):778-787. doi: 10.1093/neuros/nyy277.

PMID:
30010937
28.
29.

Value-based genomics.

Gong J, Pan K, Fakih M, Pal S, Salgia R.

Oncotarget. 2018 Jan 30;9(21):15792-15815. doi: 10.18632/oncotarget.24353. eCollection 2018 Mar 20. Review.

30.

Antimicrobial stewardship and infection prevention-leveraging the synergy: A position paper update.

Manning ML, Septimus EJ, Ashley ESD, Cosgrove SE, Fakih MG, Schweon SJ, Myers FE, Moody JA.

Am J Infect Control. 2018 Apr;46(4):364-368. doi: 10.1016/j.ajic.2018.01.001. No abstract available.

PMID:
29592832
31.

Antimicrobial Stewardship and Infection Prevention-Leveraging the Synergy: A Position Paper Update.

Manning ML, Septimus EJ, Ashley ESD, Cosgrove SE, Fakih MG, Schweon SJ, Myers FE, Moody JA.

Infect Control Hosp Epidemiol. 2018 Apr;39(4):467-472. doi: 10.1017/ice.2018.33. No abstract available.

PMID:
29576043
32.

Rationale, development, and design of the Altering Intake, Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors.

Sun V, Crane TE, Slack SD, Yung A, Wright S, Sentovich S, Melstrom K, Fakih M, Krouse RS, Thomson CA.

Contemp Clin Trials. 2018 May;68:61-66. doi: 10.1016/j.cct.2018.03.010. Epub 2018 Mar 19.

33.

The Impact of Different Postgraduate Year Training in Neurosurgery Residency on 30-Day Return to Operating Room: A National Surgical Quality Improvement Program Study.

Macki M, Fakih M, Kandagatla P, Rubinfeld I, Chang V.

World Neurosurg. 2018 Jun;114:e70-e76. doi: 10.1016/j.wneu.2018.02.068. Epub 2018 Feb 21.

PMID:
29476999
34.

Hospital-Onset Staphylococcus aureus Bacteremia Is A Better Measure Than MRSA Bacteremia for Assessing Infection Prevention: Evaluation of 50 US Hospitals.

Fakih MG, Battjes R, Sturm L, Jones L, Groves C, Bufalino A, Hendrich A.

Infect Control Hosp Epidemiol. 2018 Apr;39(4):476-478. doi: 10.1017/ice.2018.13. Epub 2018 Feb 12.

PMID:
29429428
35.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM.

Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16.

36.

"I Never Would Have Caught That Before": Pharmacist Perceptions of Using Clinical Decision Support for Antimicrobial Stewardship in the United States.

Giuliano CA, Binienda J, Kale-Pradhan PB, Fakih MG.

Qual Health Res. 2018 Apr;28(5):745-755. doi: 10.1177/1049732317750863. Epub 2018 Jan 15.

PMID:
29334865
37.

Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.

Fakih MG.

Oncologist. 2018 Apr;23(4):474-477. doi: 10.1634/theoncologist.2017-0436. Epub 2018 Jan 12.

38.

Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.

Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA.

J Gastrointest Oncol. 2017 Dec;8(6):1079-1099. doi: 10.21037/jgo.2017.09.10. Review.

39.

Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.

Chao J, Lin J, Frankel P, Clark AJ, Wiley DT, Garmey E, Fakih M, Lim D, Chung V, Luevanos E, Eliasof S, Davis ME, Yen Y.

J Gastrointest Oncol. 2017 Dec;8(6):962-969. doi: 10.21037/jgo.2017.08.10.

40.

Reducing Inappropriate Urinary Catheter Use in the Emergency Department: Comparing Two Collaborative Structures.

Greene MT, Fakih MG, Watson SR, Ratz D, Saint S.

Infect Control Hosp Epidemiol. 2018 Jan;39(1):77-84. doi: 10.1017/ice.2017.256. Epub 2017 Dec 18.

41.

A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy.

Cho M, Gong J, Frankel P, Synold TW, Lim D, Chung V, Chao J, Li D, Chen Y, Sentovich S, Melstrom K, Singh G, Luevanos E, Fakih M.

Oncotarget. 2017 Jul 18;8(45):79750-79760. doi: 10.18632/oncotarget.19336. eCollection 2017 Oct 3.

42.

A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapy-resistant colorectal cancer liver metastases.

Cho M, Kessler J, Park JJ, Lee A, Gong J, Singh G, Chen YJ, Ituarte PHG, Fakih M.

J Gastrointest Oncol. 2017 Aug;8(4):608-613. doi: 10.21037/jgo.2017.03.15.

43.

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice.

Fakih M.

J Gastrointest Oncol. 2017 Aug;8(4):603-607. doi: 10.21037/jgo.2017.07.08. No abstract available.

44.

Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention.

Reb A, Ruel N, Fakih M, Lai L, Salgia R, Ferrell B, Sampath S, Kim JY, Raz DJ, Sun V.

Eur J Oncol Nurs. 2017 Aug;29:125-134. doi: 10.1016/j.ejon.2017.06.003. Epub 2017 Jun 19.

45.

MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.

Gong J, Chen Y, Yang L, Pillai R, Shirasawa S, Fakih M.

Anticancer Res. 2017 Jun;37(6):2831-2838.

PMID:
28551618
46.

Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function.

Gong J, Cho M, Fakih M.

J Gastrointest Oncol. 2017 Apr;8(2):314-323. doi: 10.21037/jgo.2016.09.17. Review.

47.

Definitional Change in NHSN CAUTI Was Associated with an Increase in CLABSI Events: Evaluation of a Large Health System.

Fakih MG, Groves C, Bufalino A, Sturm LK, Hendrich AL.

Infect Control Hosp Epidemiol. 2017 Jun;38(6):685-689. doi: 10.1017/ice.2017.41. Epub 2017 Mar 23.

PMID:
28330520
48.

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.

Gong J, Wang C, Lee PP, Chu P, Fakih M.

J Natl Compr Canc Netw. 2017 Feb;15(2):142-147.

PMID:
28188185
49.

Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.

Gong J, Cho M, Sy M, Salgia R, Fakih M.

Oncotarget. 2017 Jun 27;8(26):42198-42213. doi: 10.18632/oncotarget.15030.

50.

Supplemental Content

Support Center